# Protective effect of statins in patients with sepsis-associated encephalopathy: a retrospective cohort study

## TL;DR

This study found that statin use is linked to lower mortality in patients with sepsis-associated encephalopathy, both short-term and long-term.

## Contribution

The study is the first to show that statins reduce mortality in sepsis-associated encephalopathy across various time points and dosages.

## Key findings

- Statin use was associated with reduced in-hospital and 30- to 365-day mortality in SAE patients.
- The protective effect of statins was consistent across different types, dosages, and exposure times.
- Atorvastatin showed similar mortality reduction as other statins in SAE patients.

## Abstract

Sepsis-associated encephalopathy (SAE) is a severe neurological complication of sepsis. Statins may exerted protective effects in sepsis and its complications by reducing the dysregulated inflammatory response. However, it remains unknown whether statins provide any protective effect on SAE.

The data for this study were extracted from the MIMIC-IV database. Cox proportional hazards regression models were constructed to assess the association between statin therapy and mortality rate for in-hospital, 30-day, 90-day, 180-day, and 365-day. Kaplan–Meier survival curves were used to estimate survival probabilities between the non-statin group and statin group. Subgroup analysis was conducted to investigate potential variations in the effects of statin treatment on clinical outcomes among different groups.

A total of 4,707 patients with SAE were included in the study, with 2,387 in the non-statin group and 2,320 in the statin group. The findings indicated that the use of statins was linked to a considerable decrease in mortality rates. Patients who were administered statins experienced lower in-hospital mortality and demonstrated enhanced survival rates at 30, 90, 180, and 365 days when compared to those not receiving statins. Further analysis of atorvastatin showed that the subgroup exhibited a similarly consistent reduction in mortality across all time points in comparison to the non-statin group. Interestingly, the protective effect associated with statin use remained significant regardless of the statin type, dosage, or exposure time.

The use of statins was associated with short-term and long-term mortality among SAE patients admitted to the ICU. This association was observed irrespective of statin type, dosage, or exposure time. It is necessary to conduct large-scale prospective studies to further explore the relationship between statins and the prognosis of patients with SAE.